360
Views
3
CrossRef citations to date
0
Altmetric
REVIEW

Osteoimmune Interactions and Therapeutic Potential of Macrophage-Derived Small Extracellular Vesicles in Bone-Related Diseases

, , & ORCID Icon
Pages 2163-2180 | Received 30 Dec 2022, Accepted 19 Apr 2023, Published online: 26 Apr 2023

Abstract

Due to the aging of the global population, the burden of bone-related diseases has increased sharply. Macrophage, as indispensable components of both innate immune responses and adaptive immunity, plays a considerable role in maintaining bone homeostasis and promoting bone establishment. Small extracellular vesicles (sEVs) have attracted increasing attention because they participate in cell cross-talk in pathological environments and can serve as drug delivery systems. In recent years, an increasing number of studies have expanded our knowledge about the effects of macrophage-derived sEVs (M-sEVs) in bone diseases via different forms of polarization and their biological functions. In this review, we comprehensively describe on the application and mechanisms of M-sEVs in various bone diseases and drug delivery, which may provide new perspectives for treating and diagnosing human bone disorders, especially osteoporosis, arthritis, osteolysis, and bone defects.

Video abstract

Point your SmartPhone at the code above. If you have a QR code reader the video abstract will appear. Or use:

https://youtu.be/-Z7d3CV4Ky4

Introduction

Extracellular vesicles (EVs) are nanovesicles with a lipid bilayer structure that are released by various cells.Citation1 In recent years, EVs have attracted extensive attention as promising alternative mediators of cell communication, and can directly affect a number of physiological and pathological processes in target cells.Citation2–4 As they have numerous advantages over conventional synthetic carriers, EVs have been considered as a next-generation drug delivery platform, opening new frontiers for modern drug delivery.Citation5,Citation6 EVs can be categorized into multiple subtypes based on their origins and physical characteristics.Citation7 Among these different subtypes of EVs, small EVs (sEVs) have been one of the most widely studied subtypes in recent years.Citation8

sEVs, with a diameter of 30–200 nm, are released by different cells, originate from the endocytic pathwayCitation7 and widely distributed in a variety of body fluids.Citation9,Citation10 All cells can release sEVs regardless of whether they are in a state of normal or pathological conditions. Due to their different sizes, levels, contents and origins, sEVs have great heterogeneity and target specific organs or cells, leading to different biological functions.Citation11 As natural endogenous nanocarriers, intercellular communication through sEVs is a crucial process for tissue progression.Citation12 sEVs, which are considered mediators of a novel mode of cell-to-cell communication, participate in intercellular signaling by transferring their encapsulated bioactive components such as RNAs, proteins, metabolites, nucleic acids, and lipids to regulate cellular behavior as a kind of signal, or by traveling to a distant body site to contribute to homeostasis and disease and are endocytosed by target cells, leading to changes in gene expression and cellular function in state of health and disease.Citation1,Citation13,Citation14

Macrophages are indispensable immune cells that contribute to both proinflammatory and anti-inflammatory processes and are involved in both tissue destruction and regeneration. Macrophages play an indispensable role in both innate immune responses and adaptive immunity and are distributed in all tissues of the body, with high plasticity and heterogeneity according to the tissue and organ in which they reside.Citation15 In response to various stimuli, macrophages can switch phenotypes from unpolarized (M0) to polarized (M1 and M2) states and play unique roles in different stages of disease status and tissue healing.Citation4,Citation16–18 Moreover, the latest opinions tend to describe that M2 macrophages can be further divided into four subtypes (M2a, M2b, M2c and M2d) according to different stimulations.Citation19,Citation20 () Macrophages perform functions that are usually related to their secretion of sEVs and microRNAs (miRNAs) carried by sEVs (). Moreover, recent studies have demonstrated that sEVs derived from macrophages play crucial roles in different biological processes, such as the immune response,Citation21 signal transduction,Citation22 cell proliferation,Citation23 and angiogenesis,Citation8 and promote or inhibit a range of diseases, such as orthopedic disorders,Citation24 chronic inflammation,Citation25 cardiovascular disease,Citation26 metabolic disorders and tumors.Citation1,Citation11,Citation27 Based on the current knowledge, this article reviews the status of investigations of sEVs secreted from macrophages and their potential application to bone diseases and aims to describe novel approaches for bone disease treatment in clinical practice.

Figure 1 Macrophage polarization. Mφs can be roughly divided into two subtypes (M1 & M2) depending on different microenvironmental stimuli. M2 Mφs can be roughly divided into four subtypes (M2a, M2b, M2c, and M2d) depending on different microenvironmental stimuli. M1 Mφs are typically induced by IFN-γ/LPS while M2 Mφs are induced by IL-4/IL-10. M1 Mφ-sEVs secrete high levels of proinflammatory cytokines, such as TNF-α, IL-1β, IL-6, IL-12, and IL-23, promoting inflammatory and cytotoxic responses. M2 Mφ-sEVs not only directly inhibit the expression of proinflammatory enzymes and cytokines, such as IL-12 and TNF-α, to achieve anti-inflammatory effects but also display higher levels of certain anti-inflammatory factors, such as IL-10 and TGF-β, thereby resolving deleterious inflammatory conditions.

Figure 1 Macrophage polarization. Mφs can be roughly divided into two subtypes (M1 & M2) depending on different microenvironmental stimuli. M2 Mφs can be roughly divided into four subtypes (M2a, M2b, M2c, and M2d) depending on different microenvironmental stimuli. M1 Mφs are typically induced by IFN-γ/LPS while M2 Mφs are induced by IL-4/IL-10. M1 Mφ-sEVs secrete high levels of proinflammatory cytokines, such as TNF-α, IL-1β, IL-6, IL-12, and IL-23, promoting inflammatory and cytotoxic responses. M2 Mφ-sEVs not only directly inhibit the expression of proinflammatory enzymes and cytokines, such as IL-12 and TNF-α, to achieve anti-inflammatory effects but also display higher levels of certain anti-inflammatory factors, such as IL-10 and TGF-β, thereby resolving deleterious inflammatory conditions.

Figure 2 The formation of small extracellular vesicles derived from macrophages. The cytoplasmic membrane of Mφs initially invaginates to form endocytic vesicles, and multiple endocytic vesicles fuse to form early-sorting endosomes (ESEs). The ESEs then invaginate, encapsulating intracellular material in the process and further transforming into late-sorting endosomes (LSEs), which are known as multivesicular bodies (MVBs). MVBs then fuse with the cytoplasmic membrane and release EVs into the extracellular space.

Figure 2 The formation of small extracellular vesicles derived from macrophages. The cytoplasmic membrane of Mφs initially invaginates to form endocytic vesicles, and multiple endocytic vesicles fuse to form early-sorting endosomes (ESEs). The ESEs then invaginate, encapsulating intracellular material in the process and further transforming into late-sorting endosomes (LSEs), which are known as multivesicular bodies (MVBs). MVBs then fuse with the cytoplasmic membrane and release EVs into the extracellular space.

Promotion of Osteogenesis

sEVs are lipid bilayer nanovesicles that are secreted by most cell types and control intercellular communication. Increasing data suggest that macrophages can establish an optimal microenvironment to reduce inflammation and promote osteogenesis through a paracrine mechanism.Citation28 sEVs derived from macrophages have been investigated as potential immunomodulatory agents in clinical therapy.Citation29,Citation30 A large number of studies have demonstrated that sEVs can be used in cell-free therapy to effectively improve bone disease and solve the problems (immune rejection, insufficient bone mass, and poor stability) caused by traditional bone implants and stem cell therapy.Citation31,Citation32

In preclinical investigations, sEVs from macrophages with different polarization phenotypes were found to have different effects on bone metabolism.Citation4 Based on the observations that macrophages contribute to bone regeneration, macrophage polarization to the M1 phenotype may be essential during the early phases of osteoinduction and bone regeneration, and the M2 phenotype may foster continued bone regeneration.Citation30 Huang et al demonstrated that sEVs secreted by M1 macrophages promoted the proliferation and osteogenic and adipogenic differentiation of bone marrow mesenchymal stem cells (BMSCs). However, the sEVs secreted by M2 macrophages impaired the proliferation of BMSCs. M0-sEVs exhibit no considerable influence on the proliferation of BMSCs.Citation33 Another study indicated that sEVs from M1 macrophages attenuated cementoblast mineralization, while sEVs from M2 macrophages facilitated cementoblast mineralization.Citation4 During tissue healing and regeneration, biomimetic intrafibrillarly mineralized collagen (IMC) was found to regulate M2 macrophage polarization and secrete sEVs. Human BMSCs were cultured in osteogenic medium supplemented with IMC-sEVs. IMC-sEVs promoted BMSC osteogenic differentiation by increasing the expression levels of BMP2 and Smad5 (one of the classic proteins of the osteogenic pathway). Blockade of sEV secretion by GW4869 significantly impaired BMSC osteogenesis.Citation26

In recent years, the function and potential application of miRNAs in osteogenic differentiation have attracted increasing attention. MiR-690 enriched in M2-sEVs could facilitate osteogenesis and reduce adipogenesis by upregulating the levels of IRS-1 and TAZ, suggesting a potential role of M2-sEVs as a therapeutic tool for bone loss.Citation34 Macrophage-derived sEVs containing miR-381 suppress the osteogenic differentiation of BMSCs by reducing the levels of ALP and Runx2, and the effect could be reversed by a miR-381 inhibitor. Mg2+ is essential for the maintenance of physiological homeostasis in tissues and organs and has been verified to significantly decrease miR-381 expression and further facilitate the osteogenic differentiation of BMSCs.Citation35 IL-10 is considered to be a crucial regulator of bone homeostasis and inflammatory conditions, playing a prominent role in regulating osteoblast/osteoclast differentiation and function. M2-sEVs could upregulate IL-10 cytokine expression in BMSCs and bone marrow-derived macrophages (BMDMs) by delivering IL-10 mRNA to cells directly, leading to the activation of the cellular IL-10/IL-10R pathway to regulate cell differentiation and bone metabolism and preventing bone loss in murine periodontitis models.Citation36

Promotion of Osseointegration

Angiogenesis and osteogenesis are essential preconditions for achieving favorable osseointegration of the bone implants. Increasing evidence has demonstrated that osteoimmunomodulation mediated by macrophage-derived sEVs plays a pivotal role in angiogenesis and osteogenesis.Citation37,Citation38 sEVs can be internalized by various cells participating in bone formation, such as endothelial cells and osteoblasts, to intervene in the osseointegration.

In one study, sEVs derived from bone morphogenetic protein 2 (BMP2)- stimulated macrophages were used to modify titanium nanotube implants. The incorporation dramatically increased the expression of early osteoblastic differentiation markers, ALP, Runx2 and BMP2; promoted the osteogenic differentiation of BMSCs; activated autophagy of hBMSCs; and altered the secretion of cytokines associated with bone remodeling, indicating the important effects of macrophage-sEVs in osseointegration.Citation39 Titanium and titanium alloys are the most widely used implant materials in clinics due to their good biocompatibility and mechanical properties and have an important influence on osseointegration. Mouse RAW264.7 cells stimulated with titanium disks (Ti6Al4V) were found to polarize into the anti-inflammatory M2 phenotype. sEVs derived from M2 macrophages induced upregulation of osteoblast differentiation marker genes Runx2 and CoL-1 in MC3T3-E1 cells. Moverover, several miRNAs involved in the progress of osseointegration were upregulated or downregulated, indicating that M2-sEVs played an important role in the process of osteoimmunity-promoting osseointegration.Citation40 Another study confirmed that sEVs extracted from macrophages cultured with titania nanotube arrays anodized with a voltage of 40 V (TNA-40) can significantly upregulate the ALP activity and osteogenic-related gene expression of BMSCs, promote endothelial cell (EC) migration, and enhance angiogenic capacity through the interaction between miR-3473e and the target gene Akt1.Citation41 The immunosuppressive and anti-inflammatory molecule ADA2AR has been proven to enhance the proliferation and migration of vascular endothelial cells (VECs) and promote angiogenesis and the selection of M-sEVs during bone healing. However, the underlying mechanism warrants further research.Citation16 sEVs derived from alternatively activated M2 macrophages can induce in situ direct conversion of classic activated M1 macrophages into reprogrammed M2-like phenotype to promote cutaneous wound healing and repair by enhancing angiogenesis and re-epithelialization.Citation42

Promotion of Tissue Repair and Regeneration

Macrophage-derived sEVs may serve as an emerging functional tool in biomaterial-mediated endogenous bone regeneration. Macrophages with different polarization phenotypes influence cementoblast mineralization through sEVs, M1 macrophages attenuate mineralization, and M2 macrophages enhance mineralization.Citation43 In a diabetic wound rat model, macrophage-derived sEVs exerted anti-inflammatory effects by inhibiting the secretion of proinflammatory enzymes and cytokines, weakening the infiltration of inflammatory cells, and inducing endothelial cell proliferation and migration to improve angiogenesis and re-epithelialization to further promote diabetic wound repair.Citation44

M-sEVs and Bone Diseases

Macrophages have been recognized as essential regulators of bone homeostasis.Citation45,Citation46 M-sEVs play a crucial role in bone diseases by interfering with osteoblast differentiation, osteogenesis, angiogenesis, cell proliferation, apoptosis, the immune response, and inflammatory factors. sEVs derived from different macrophage subtypes perform diverse functions (M0-sEVs in and , M1-sEVs in and , M2-sEVs in and ).

Table 1 Published Studies on Biogenesis of M0-Macrophage (M0-Mφ) Derived sEVs in Bone-Related Diseases

Table 2 Published Studies on Biogenesis of sEVs Derived from M1-Macrophage (M1-Mφ) in Bone-Related Diseases

Table 3 Published Studies on Biogenesis of sEVs Derived from M2-Macrophage (M2-Mφ) in Bone-Related Diseases

Figure 3 Published data on the biogenesis of sEVs derived from M0 macrophages in bone-related diseases.

Figure 3 Published data on the biogenesis of sEVs derived from M0 macrophages in bone-related diseases.

Figure 4 Published data on the biogenesis of sEVs derived from M1 macrophages in bone-related diseases.

Figure 4 Published data on the biogenesis of sEVs derived from M1 macrophages in bone-related diseases.

Figure 5 Published data on the biogenesis of sEVs derived from M2 macrophages in bone-related diseases.

Figure 5 Published data on the biogenesis of sEVs derived from M2 macrophages in bone-related diseases.

Bone Fracture or Defect

Bone fracture is a common clinical challenge and easily causes compromised physical activity, loss of productivity, and decreased quality of life. Osteoblast differentiation of MSCs is an important process during fracture healing. Studies have shown that during the early stage of the proinflammatory response, miRNA-21a-5p, which is overexpressed by M1-sEVs can promote the osteogenic differentiation of BMSCs.Citation47 During the anti-inflammatory response that occurs during the late stages of the disease, M2-sEVs overexpressing miRNA-5106 were found to inhibit the expression of salt-induced kinases 2 and 3 (SIK2 and SIK3) to promote osteoblast differentiation and bone mineral deposition, and accelerate fracture healing.Citation48 MiR-26a-5p carried by sEVs from M2 macrophages actively promoted the expression of the bone differentiation-related proteins ALP, RUNX-2, OPN, and CoL-2 in BMSCs, and the effect could be attenuated by the inhibitor GW4689. MiR-26a-5p in M2-sEVs can promote osteogenic differentiation and inhibit adipogenic differentiation, indicating a positive role during bone fracture healing.Citation49

Bone defects resulting from fractures and disease are a medical concern, and are often unable to heal spontaneously by the body’s repair mechanisms. Macrophage-derived sEVs may serve as an emerging functional tool in biomaterial-mediated endogenous bone regeneration. MiR-155-encriched M1-sEVs were found to impair osteoblastic differentiation by reducing the expression of BMP2, BMP9 and RUNX2. MiR-378a contained in M2-sEVs acts as a positive regulator of osteogenesis by specifically activating upon the BMPS signal transduction pathway. The expression of BMP2 and BMP9 in MSCs increased after miR-378a was transferred into calvaria defect rats.Citation4

Osteoporosis

Osteoporosis is considered as the most prevalent bone disorder in elderly people worldwide and is characterized by low bone mass, deterioration of bone tissue and decreased bone strength. When people are experience estrogen deficiency, aging, high levels of glucocorticoids, inflammation and hyperparathyroidism, the balance between the activities of bone-forming osteoblasts and bone-resorbing osteoclasts is disrupted, causing the occurrence of osteoporosis.Citation14,Citation50–52 Osteoporosis is more common in women than in men, and is a strong risk factor for fragility fractures in untreated people. It is estimated that 40% of postmenopausal women and 30% of older men (over 70 years of age) are at risk of experiencing osteoporotic fractures and the number continues to increase, posing tremendous medical and economic challenges to patients and society.Citation53 Type 2 diabetes mellitus (T2DM) is a common cause of secondary osteoporosis. Microvascular complications of T2DM lead to reduced blood flow to bone and may contribute to bone loss and its fragility, leading to an increased risk of bone fracture.Citation54 MiR-144-5p, which was derived from diabetic bone marrow-derived macrophage (dBMDM)-sEVs, could be transferred into BMSCs to suppress bone regeneration by targeting Smad1 and impair bone repair in vitro and vivo, increasing the risk of delayed bone union and nonunion and doubling the time of fracture healing associated with diabetes.Citation55 The osteogenic differentiation of BMSCs is impaired under high-glucose and high-insulin (HGI) conditions in vitro. The effect is partially relieved by the intervention of M2 macrophage-derived sEVs through activating the Hedgehog signaling pathway. The ALP activity of BMSCs in the HGI group was found to be lower than that in the control group. After intervention with M2-sEVs, ALP activity was significantly higher than that in the HGI group. In addition, the expression of the osteogenesis-related proteins COL1A1 and GLI1 is upregulated after M2-sEV treatment, suggesting that M2-sEVs have therapeutic potential for the treatment of diabetic bone disease.Citation56 In a mouse model of postmenopausal osteoporosis, miR-98 enriched in M1-sEVs could exacerbate bone loss by downregulating the expression of dual specificity phosphatase 1 (DUSP1) activating the JNK signaling pathway.Citation57

Muscle Injury and Tendinopathy

Muscle injuries such as tendon tears and tendinopathies are common and easily cause considerable disability, pain, health care costs, and losses productivity. Following tendon injury, the development of fibrotic healing response impairs tendon function and restricts tendon motion. Peritendinous tissue fibrosis poses a major clinical problem in hand surgery. sEVs from macrophages are crucial factors in tissue microenvironment regulation following tissue injury. Macrophage-derived miR-21-5p-enriched sEVs lead to increased proliferation, migration, and fibrotic activity of tendon cells by inhibiting the expression of Smad7, providing potential targets for the prevention and treatment of tendon adhesion.Citation58 MiR-501 overexpressed in M2-sEVs can be transferred into myoblasts, downregulate the expression of the transcription factor YY1, affect myoblast differentiation and promote the formation of myotubes, thus leading to regeneration of injured pubococcygeal muscle.Citation59 M2 macrophage-derived circRNA-Ep400-containing sEVs inhibited miR-15b-5p but promoted the expression of Col-I, Col-III, α-SMA and FGF1/7/9 in both fibroblasts and tenocytes, thus promoting peritendinous fibrosis and providing novel therapeutics for tendon injury treatment.Citation60

Inflammation and Bone Osteolytic Diseases

Inflammatory-mediated pathological bone osteolytic diseases including osteoarthritis (OA), rheumatoid arthritis (RA), immunoinflammatory osteolysis, aseptic prosthesis loosening, and periodontitis are major orthopedic diseases that cause disability and impose a substantial economic burden worldwide.Citation61,Citation62 Bone remodeling is a process involving osteoblast formation and osteoclast resorption to maintain bone architecture balance and systemic mineral homeostasis.Citation63 Chronic inflammation caused by various factors can disrupt this delicate balance between osteoblasts and osteoclasts and disturb bone metabolism, causing osteolytic disorders.Citation64 Macrophages play a substantial role in bone diseases caused by chronic inflammation.Citation64 Proteomic studies have shown that macrophage-derived sEVs contain a large number of proteins, such as alarmins, chemokines, and inflammatory cytokines and play a critical role in bone remodeling as vehicles.Citation65 Alarmins are endogenous molecules often detected in macrophage-sEVs that include annexins, galectins, heat-shock proteins and S100-alarmins, which are released upon cellular stress and activate the immune system.Citation66–68 Alarmins play wide roles in osteocyte, osteoblast and osteoclast differentiation and function. Annexin2 in macrophage sEVs can stimulate bone resorption by promoting the overexpression of the pro-osteoclastogenic factors GM-CSF and RANKL, and facilitating osteoclast formation.Citation69 Galectin-3 as a regulator of the osteoblast-osteoclast interaction inhibits osteoclastogenesis and regulates bone homeostasis.Citation70 Increased HSP60 levels stimulated by IL-1β and TNF-α can promote osteoclast formation and activity by activating RANK-RANKL signaling by binding to TLR2.Citation71 IL-1β, a critical inflammatory cytokine in the inflammatory cascade response, is also contained in macrophage-sEVs. It stimulates the production of various proinflammatory mediators, such as cytokines, chemokines, and matrix metalloproteinases (MMPs), leading to the continued progression of chronic inflammation.Citation72,Citation73 In inflammatory conditions, LPS/IFN-γ can stimulate macrophages to secrete endoplasmic reticulum aminopeptidase 1 (ERAP1) via sEVs to enhance the phagocytic and nitric oxide (NO) synthetic activities of macrophages and modify inflammatory reactions.Citation74 Similarly, macrophages secrete pro- and anti-inflammatory mediators into the micro milieu to regulate bone homeostasis in inflammatory conditions. During the inflammatory phase, the production and release of sEVs are abundant and easily cause tissue cell hypoxia due to the increase in cell metabolism and the reduction in the levels of substrates. Under hypoxic conditions, sEVs enriched with miR-222 derived from M1 macrophages can be released to target BMSCs, inducing cell apoptosis and thereby regulating bone formation.Citation75 MiR-222 has also been reported to inhibit endothelial cell migration, proliferation, and angiogenesis by suppressing the production of nitric oxide synthase.Citation76 Under inflammatory conditions, chemokines and proinflammatory cytokines (IFN-γ, LPS, and IL-1β) are produced and induce polarization of M1 macrophages. MiR-155 is derived from M1 macrophage sEVs and transferred into endothelial cells, controlling endothelial cell migration and cell-cell connections, thereby regulating vascular permeability.Citation38,Citation77

Osteoarthritis

Osteoarthritis is the most common form of joint disease and is characterized by pain, cartilage destruction, synovial fibrosis osteophyte formation, and sometimes the swelling of certain joints such as the hand, spine, hip and knee, and is frequently accompanied by synovitis.Citation78 Multiple studies have confirmed that macrophages play an important role in the occurrence of OA through inflammatory factors, cytokines, miRNA and proteins.Citation79 The long noncoding RNA (lncRNA) MM2P induces M2 macrophage polarization, and promotes the spread of SOX9 enriched in M2-sEVs into chondrocytes, significantly enhancing the differentiation and function of chondrocytes, which promotes cartilage repair and supports a novel therapeutic strategy for OA.Citation80 Knee OA (KOA) is a degenerative disease with the main symptoms of cartilage destruction and knee joint pain, resulting in the activation of the PI3K/Akt/mTOR signaling pathway in the body. sEVs derived from M2 macrophage intervention can inhibit the protein and mRNA expression of PI3K, Akt, and mTOR in KOA model rats and reduce cartilage injury, indicating that M2-sEVs may exert a therapeutic effect on KOA, but the mechanism is still unclear.Citation81

Rheumatoid Arthritis

RA is one of the most widespread chronic inflammatory joint diseases with strong genetic predisposition factors and is characterized by synovitis, cartilage erosion and bone loss accompanied by pain, swelling, stiffness, and joint deformity, and can also damage extra-articular organs, such as the heart, kidney, lung and nervous system.Citation82,Citation83 MiR-223 is enriched in macrophage-sEVs under inflammatory conditions.Citation84 As an innate immune regulatory factor, the expression of miR-223 is highest in the bone marrow cavity, playing an important role in the differentiation of granulocytes and macrophages during the differentiation of bone marrow. MiR-223 activates the immune system, promotes macrophage polarization to the anti-inflammatory M2 type, and induces the production of more sEVs.Citation38,Citation85 Another study revealed the multiple roles that miR-223 plays in bone metabolism by regulating osteoclast differentiation, representing a promising diagnostic tool for the treatment of bone diseases related to aberrant bone metabolism.Citation86 Another study also showed that miR-223 derived from macrophages can induce the differentiation of monocytes, activate hematopoietic cell production in the marrow, and promote the release of more sEVs. Thus, this feedback mechanism may be an innate response element that regulates host defense and inflammation.Citation87

Immunoinflammatory Osteolysis and Aseptic Loosening

Aseptic loosening is a common complication following total joint arthroplasty due to periprosthetic inflammatory osteolysis and is the leading cause of revision procedures.Citation88,Citation89 Wear particles released from the sliding surfaces of prosthetic materials induce a persistent local inflammatory response, thereby stimulating bone resorbing-osteoclast activities and bone loss around the implant.Citation90,Citation91 Macrophages activated by wear particulate debris release an array of cytokines and proinflammatory mediators in the joint fluid and facilitate the recruitment of inflammatory cells.Citation92,Citation93 MiR-155 can be stimulated by activators of proinflammatory M1 phenotype macrophages (LPS, IFN-α) and released to promote the secretion of inflammatory cytokines such as TNF-α and IL-12, thereby aggravating the inflammatory response.Citation94 The production of miR-23a-5p-containing sEVs induced by RANKL effectively inhibits the expression of Runx2 and suppresses osteoblast differentiation.Citation95

Periodontitis

Chronic periodontitis is one of the most common diseases of the oral and maxillofacial regions and is caused by bacterial infection and the host immune-inflammatory response, leading to alveolar bone absorption and tooth loosening and shedding.Citation96 Porphyromonas gingivalis (P.g) is the major pathogenic bacterium involved in chronic periodontitis. A recent study revealed that P.g-LPS-activated macrophage-derived sEVs can inhibit BMSC osteogenic differentiation by mediating inflammatory stimulation. P.g LPS-stimulated macrophages produced an inflammatory response and released sEVs. After BMSCs had taken up inflammatory sEVs, the gene and protein expression levels of TNF-α and IL-6 were significantly unregulated, but the expression of ALP, RUNX2, and COL-1 decreased, indicating an inhibitory effect on BMSCs in inflammatory states.Citation97

Osteosarcoma and Tumor Bone Metastasis

Osteosarcoma (OS) is one of the most common primary malignant bone tumors in adolescents, and in general, it occurs in males more frequently than in females.Citation98 sEVs from macrophages have been reported to play critical roles in regulating the proliferation, metastasis, and angiogenesis of osteosarcoma by participating in intercellular contacts and controlling cellular signaling.Citation99 LIFR-AS1 as a newly described tumor-related lncRNA, has been reported to be released from macrophages to osteosarcoma cells via sEVs and further promote tumor progression by acting as a sponge in the miR-29a/NFIA pathway.Citation100 Bone is one of the most common metastatic sites of breast cancer. sEVs enriched in miR-223 secreted from IL-4-activated macrophages were found to promote breast cancer cell invasion through the miR-223/Mef2c/β-catenin pathway.Citation101 sEVs containing miR‑660 derived from tumor-associated macrophages promoted the invasion and migration of breast cancer cells by inhibiting KLHL21 activity and then increased bone and lung lymph node metastasis.Citation102

Drug Delivery

sEVs have been demonstrated to be endogenous delivery carriers with excellent biocompatibility, low cytotoxicity, and immunological inertness and are an ideal potential candidate for the treatment of many diseases. Numerous studies have shown that sEVs derived from macrophages can carry various drugs, such as protein, DNA and small molecular drugs, and play a role in inflammatory regulation. IL4-loaded sEVs exhibit high anti-inflammatory effects by modulating macrophage polarization. IL4-sEVs are absorbed by macrophages via endocytosis and regulate the M1/M2 status and suppress downstream fibroblast proliferation, pannus formation, and bone destruction in CIA mice. In the synovium of RA joints, IL4-sEV-infiltrated macrophages predominantly secrete proinflammatory mediators, which are expected to contribute to the in vivo anti-inflammatory effects and are considered for the treatment of chronic inflammatory rheumatoid arthritis.Citation103,Citation104 Another study showed M2 sEVs/pDNA/BSP nanoparticles using M2-sEVs as a platform for the codelivery of IL-10 pDNA and the chemotherapeutic drug betamethasone sodium phosphate (BSP), which can effectively increase IL-10 secretion, attenuate the production of proinflammatory cytokines (IL-1β, TNF-α), promote macrophage polarization from a proinflammatory to an anti-inflammatory state, and efficiently reduce joint damage for RA treatment.Citation105 Engineered M2-sEVs loaded with FDA-approved hexyl 5-aminolevulinate hydrochloride (HAL) exhibited excellent inflammatory-tropism and anti-inflammatory effects via surface-bonded chemokine receptors and anti-inflammatory cytokines derived from M2 macrophages. The encapsulated HAL can facilitate the biosynthesis of anti-inflammatory carbon monoxide and bilirubin and further enhance anti-inflammatory effects.Citation106 Curcumin is a natural polyphenol with anti-inflammatory, antineoplastic and antioxidant activities. Curcumins complexed with sEVs (Cur-sEVs) have been found to have increased stability and bioavailability. Macrophages treated with Cur-sEVs produced significantly lower levels of IL-6 and TNF-α than macrophages treated with curcumin or sEV treatment alone, indicating a higher anti-inflammatory activity.Citation107 Dexamethasone sodium phosphate encapsulated in M-sEVs (Dex/sEVs) showed an anti-inflammatory effect on macrophages by suppressing the expression of proinflammatory cytokines (IL-1β, TNF-α, and IL-6) and increasing the levels of anti-inflammatory cytokines (IL-10), promoting the bone and cartilage repair and significantly reducing the incidence of inflamed joints in CIA mice.Citation108 For the application of sEVs to achieve good therapeutic effects, safe manufacturing, quality control, and scalable mass production solutions are needed. Thus, optimized technologies need to be developed in the future to facilitate the clinical use of sEV delivery.

Discussion and Future Perspectives

Orthopedic diseases constitute one of the major causes of disability and impose a considerable economic burden worldwide. Macrophages play an important role in maintaining bone homeostasis and promoting bone establishment. sEVs derived from macrophages, which act as mediators of intercellular communication are potential immunomodulatory agents investigated in the context of basic research and clinical therapy. This paper describes the contribution of sEVs derived from macrophages in bone diseases and provides a theoretical basis for further research and the clinical application of sEVs as ideal candidates for drug delivery systems in the treatment of orthopedic diseases in the future. sEVs, as an important medium of communication between cells, can mediate bone metabolism through the paracrine transmission of various bioactive substances.Citation30,Citation109 We focused on miRNAs and intracellular proteins as key mediators of sEV effects on bone homeostasis. In addition, due to the advantages of lower toxicity and immunogenicity, higher biocompatibility, natural targeting ability, and good biological barrier permeability, their carrier functions can be used for more complex scenarios than lipid nanoparticles. M-sEVs have been used as a vehicle for the delivery of drugs with remarkable inflammatory tropism and anti-inflammatory effects.Citation110 However, it is difficult to determine the exact dose and timing for application, and basic research and preclinical exploration of the specific mechanism of sEVs for intercellular communication under physiological and pathological conditions are still an immature stage. The contents of sEVs are complex, which hinders further exploration of their mechanisms of action. The exact mechanisms of sEVs still need to be further investigated and the application of engineered sEVs for clinical regeneration requires continued study of safety, feasibility and mass productivity.

Conclusion

M-sEVs play important roles in the mechanism of bone disease by interfering with osteogenesis, angiogenesis, epithelialization, cell proliferation and migration, differentiation, the immune response, inflammatory factors and others. They participate in a variety of pathways associated with bone homeostasis and can be used as drug carriers. It is believed that M-sEVs have great therapeutic potential in all aspects of medical treatment in the future development of biotechnology.

Disclosure

The authors report no conflicts of interest in this work.

Additional information

Funding

This work was partially supported by the Natural Science Foundation of Shandong Province (No. ZR2021QH307; No. ZR2021MH013), China Scholarship Council (CSC) (NO. 201808080126), the incubation fund of Shandong Provincial Hospital (grant number 2020FY019), Young Scholars Program of Shandong Provincial Hospital, the Shandong Province Major Scientific and Technical Innovation Project (No. 2021SFGC0502), and the Jinan Clinical Medical Science and Technology Innovation Plan (NO. 202019168). The authors, their immediate families, and any research foundations with which they are affiliated have not received any financial payments or other benefits from any commercial entity related to the subject of this article.

References

  • Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977. doi:10.1126/science.aau6977
  • Shahin HI, Radnaa E, Tantengco OAG, et al. Microvesicles and exosomes released by amnion epithelial cells under oxidative stress cause inflammatory changes in uterine cells dagger. Biol Reprod. 2021;105(2):464–480. doi:10.1093/biolre/ioab088
  • Kim SD, Kang SA, Kim YW, et al. Screening and functional pathway analysis of pulmonary genes associated with suppression of allergic airway inflammation by adipose stem cell-derived extracellular vesicles. Stem Cells Int. 2020;2020:5684250. doi:10.1155/2020/5684250
  • Kang M, Huang CC, Lu Y, et al. Bone regeneration is mediated by macrophage extracellular vesicles. Bone. 2020;141:115627. doi:10.1016/j.bone.2020.115627
  • Herrmann IK, Wood MJA, Fuhrmann G. Extracellular vesicles as a next-generation drug delivery platform. Nat Nanotechnol. 2021;16(7):748–759. doi:10.1038/s41565-021-00931-2
  • Liu H, Zhang Q, Wang S, et al. Bacterial extracellular vesicles as bioactive nanocarriers for drug delivery: advances and perspectives. Bioact Mater. 2022;14:169–181. doi:10.1016/j.bioactmat.2021.12.006
  • Thery C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the international society for extracellular vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7(1):1535750. doi:10.1080/20013078.2018.1535750
  • Lawson C, Vicencio JM, Yellon DM, Davidson SM. Microvesicles and exosomes: new players in metabolic and cardiovascular disease. J Endocrinol. 2016;228(2):R57–71. doi:10.1530/JOE-15-0201
  • Ye J, Liu X. Macrophage-derived small extracellular vesicles in multiple diseases: biogenesis, function, and therapeutic applications. Front Cell Dev Biol. 2022;10:913110. doi:10.3389/fcell.2022.913110
  • Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2(8):569–579. doi:10.1038/nri855
  • Mathieu M, Martin-Jaular L, Lavieu G, Thery C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol. 2019;21(1):9–17. doi:10.1038/s41556-018-0250-9
  • Moller A, Lobb RJ. The evolving translational potential of small extracellular vesicles in cancer. Nat Rev Cancer. 2020;20(12):697–709. doi:10.1038/s41568-020-00299-w
  • Gong L, Chen B, Zhang J, et al. Human ESC-sEVs alleviate age-related bone loss by rejuvenating senescent bone marrow-derived mesenchymal stem cells. J Extracell Vesicles. 2020;9(1):1800971. doi:10.1080/20013078.2020.1800971
  • Liang G, Kow ASF, Tham CL, Ho YC, Lee MT. Ameliorative effect of tocotrienols on perimenopausal-associated osteoporosis-A review. Antioxidants. 2022;11:11. doi:10.3390/antiox11112179
  • Shapouri-Moghaddam A, Mohammadian S, Vazini H, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol. 2018;233(9):6425–6440. doi:10.1002/jcp.26429
  • Wang D, Wang J, Zhou J, Zheng X. The role of adenosine receptor A2A in the regulation of macrophage exosomes and vascular endothelial cells during bone healing. J Inflamm Res. 2021;14:4001–4017. doi:10.2147/JIR.S324232
  • Chen K, Jiao Y, Liu L, et al. Communications between bone marrow macrophages and bone cells in bone remodeling. Front Cell Dev Biol. 2020;8:598263. doi:10.3389/fcell.2020.598263
  • Pieters BCH, Cappariello A, van den Bosch MHJ, et al. Macrophage-derived extracellular vesicles as carriers of alarmins and their potential involvement in bone homeostasis. Front Immunol. 2019;10:1901. doi:10.3389/fimmu.2019.01901
  • Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889–896. doi:10.1038/ni.1937
  • Roszer T. Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. Mediators Inflamm. 2015;2015:816460. doi:10.1155/2015/816460
  • Bai ZZ, Li HY, Li CH, Sheng CL, Zhao XN. M1 macrophage-derived exosomal MicroRNA-326 suppresses hepatocellular carcinoma cell progression via mediating NF-kappaB signaling pathway. Nanoscale Res Lett. 2020;15(1):221. doi:10.1186/s11671-020-03432-8
  • Gangoda L, Boukouris S, Liem M, Kalra H, Mathivanan S. Extracellular vesicles including exosomes are mediators of signal transduction: are they protective or pathogenic? Proteomics. 2015;15(2–3):260–271. doi:10.1002/pmic.201400234
  • Zhu G, Xia Y, Zhao Z, et al. LncRNA XIST from the bone marrow mesenchymal stem cell derived exosome promotes osteosarcoma growth and metastasis through miR-655/ACLY signal. Cancer Cell Int. 2022;22(1):330. doi:10.1186/s12935-022-02746-0
  • Zhou QF, Cai YZ, Lin XJ. The dual character of exosomes in osteoarthritis: antagonists and therapeutic agents. Acta Biomater. 2020;105:15–25. doi:10.1016/j.actbio.2020.01.040
  • Yang R, Liao Y, Wang L, et al. Exosomes derived from M2b macrophages attenuate DSS-induced colitis. Front Immunol. 2019;10:2346. doi:10.3389/fimmu.2019.02346
  • Liu S, Chen J, Shi J, et al. M1-like macrophage-derived exosomes suppress angiogenesis and exacerbate cardiac dysfunction in a myocardial infarction microenvironment. Basic Res Cardiol. 2020;115(2):22. doi:10.1007/s00395-020-0781-7
  • Zhang Y, Liu Y, Liu H, Tang WH. Exosomes: biogenesis, biologic function and clinical potential. Cell Biosci. 2019;9:19. doi:10.1186/s13578-019-0282-2
  • Liu A, Jin S, Fu C, et al. Macrophage-derived small extracellular vesicles promote biomimetic mineralized collagen-mediated endogenous bone regeneration. Int J Oral Sci. 2020;12(1):33. doi:10.1038/s41368-020-00100-6
  • McKelvey KJ, Powell KL, Ashton AW, Morris JM, McCracken SA. Exosomes: mechanisms of Uptake. J Circ Biomark. 2015;4:7. doi:10.5772/61186
  • Meng F, Xue X, Yin Z, et al. Research progress of exosomes in bone diseases: mechanism, diagnosis and therapy. Front Bioeng Biotechnol. 2022;10:866627. doi:10.3389/fbioe.2022.866627
  • Bjorge IM, Kim SY, Mano JF, Kalionis B, Chrzanowski W. Extracellular vesicles, exosomes and shedding vesicles in regenerative medicine - a new paradigm for tissue repair. Biomater Sci. 2017;6(1):60–78. doi:10.1039/c7bm00479f
  • Huang J, Xiong J, Yang L, et al. Cell-free exosome-laden scaffolds for tissue repair. Nanoscale. 2021;13(19):8740–8750. doi:10.1039/d1nr01314a
  • Huang X, Lan Y, Shen J, Chen Z, Xie Z. Extracellular vesicles in bone homeostasis: emerging mediators of osteoimmune interactions and promising therapeutic targets. Int J Biol Sci. 2022;18(10):4088–4100. doi:10.7150/ijbs.69816
  • Li Z, Wang Y, Li S, Li Y. Exosomes derived from M2 macrophages facilitate osteogenesis and reduce adipogenesis of BMSCs. Front Endocrinol. 2021;12:680328. doi:10.3389/fendo.2021.680328
  • Zhu Y, Zhao S, Cheng L, et al. Mg(2+) -mediated autophagy-dependent polarization of macrophages mediates the osteogenesis of bone marrow stromal stem cells by interfering with macrophage-derived exosomes containing miR-381. J Orthop Res. 2022;40(7):1563–1576. doi:10.1002/jor.25189
  • Chen X, Wan Z, Yang L, et al. Exosomes derived from reparative M2-like macrophages prevent bone loss in murine periodontitis models via IL-10 mRNA. J Nanobiotechnology. 2022;20(1):110. doi:10.1186/s12951-022-01314-y
  • Bai L, Zhao Y, Chen P, et al. Targeting early healing phase with titania nanotube arrays on tunable diameters to accelerate bone regeneration and osseointegration. Small. 2021;17(4):e2006287. doi:10.1002/smll.202006287
  • Xiao Y, Ding Y, Zhuang J, et al. Osteoimmunomodulation role of exosomes derived from immune cells on osseointegration. Front Bioeng Biotechnol. 2022;10:989537. doi:10.3389/fbioe.2022.989537
  • Wei F, Li M, Crawford R, Zhou Y, Xiao Y. Exosome-integrated titanium oxide nanotubes for targeted bone regeneration. Acta Biomater. 2019;86:480–492. doi:10.1016/j.actbio.2019.01.006
  • Zhang T, Jiang M, Yin X, Yao P, Sun H. Mechanism of exosomes involved in osteoimmunity promoting osseointegration around titanium implants with small-scale topography. Front Bioeng Biotechnol. 2021;9:682384. doi:10.3389/fbioe.2021.682384
  • Wang Z, Zhao F, Zhao Y, Bai L, Hang R. Simultaneously enhanced osteogenesis and angiogenesis via macrophage-derived exosomes upon stimulation with titania nanotubes. Biomater Adv. 2022;134:112708. doi:10.1016/j.msec.2022.112708
  • Kim H, Wang SY, Kwak G, et al. Exosome-guided phenotypic switch of M1 to M2 macrophages for cutaneous wound healing. Adv Sci. 2019;6(20):1900513. doi:10.1002/advs.201900513
  • Zhao Y, Huang Y, Liu H, et al. Macrophages with different polarization phenotypes influence cementoblast mineralization through exosomes. Stem Cells Int. 2022;2022:4185972. doi:10.1155/2022/4185972
  • Li M, Wang T, Tian H, et al. Macrophage-derived exosomes accelerate wound healing through their anti-inflammation effects in a diabetic rat model. Artif Cells Nanomed Bio. 2019;47(1):3793–3803. doi:10.1080/21691401.2019.1669617
  • Zhang Q, Sun W, Li T, Liu F. Polarization behavior of bone macrophage as well as associated osteoimmunity in glucocorticoid-induced osteonecrosis of the femoral head. J Inflamm Res. 2023;16:879–894. doi:10.2147/JIR.S401968
  • Zhang Q, Lu S, Zhou D, Dong J, Liu F. PTGS2 identified as a biomarker of glucocorticoid-induced osteonecrosis of the femoral head and an enhancer of osteogenesis. Genes & Diseases. 2023;10:14–17. doi:10.1016/j.gendis.2022.01.005
  • Liu K, Luo X, Lv ZY, et al. Macrophage-derived exosomes promote bone mesenchymal stem cells towards osteoblastic fate through microRNA-21a-5p. Front Bioeng Biotechnol. 2021;9:801432. doi:10.3389/fbioe.2021.801432
  • Xiong Y, Chen L, Yan C, et al. M2 Macrophagy-derived exosomal miRNA-5106 induces bone mesenchymal stem cells towards osteoblastic fate by targeting salt-inducible kinase 2 and 3. J Nanobiotechnology. 2020;18(1):66. doi:10.1186/s12951-020-00622-5
  • Bin-Bin Z, Da-Wa ZX, Chao L, et al. M2 macrophagy-derived exosomal miRNA-26a-5p induces osteogenic differentiation of bone mesenchymal stem cells. J Orthop Surg Res. 2022;17(1):137. doi:10.1186/s13018-022-03029-0
  • Arceo-Mendoza RM, Camacho PM. Postmenopausal osteoporosis: latest guidelines. Endocrinol Metab Clin North Am. 2021;50(2):167–178. doi:10.1016/j.ecl.2021.03.009
  • Liu F, Dong J, Zhang P, Zhou D, Zhang Q. Transcriptome sequencing reveals key genes in three early phases of osteogenic, adipogenic, and chondrogenic differentiation of bone marrow mesenchymal stem cells in rats. Front Mol Biosci. 2021;8:782054. doi:10.3389/fmolb.2021.782054
  • Zhang Q, Dong J, Zhang P, Zhou D, Liu F. Dynamics of transcription factors in three early phases of osteogenic, adipogenic, and chondrogenic differentiation determining the fate of bone marrow mesenchymal stem cells in rats. Front Cell Dev Biol. 2021;9:768316. doi:10.3389/fcell.2021.768316
  • Mitchell PJ, Chan DD, Lee JK, Tabu I, Alpuerto BB. The global burden of fragility fractures - what are the differences, and where are the gaps. Best Pract Res Clin Rheumatol. 2022;36:101777. doi:10.1016/j.berh.2022.101777
  • Hygum K, Starup-Linde J, Langdahl BL. Diabetes and bone. Osteoporos Sarcopenia. 2019;5(2):29–37. doi:10.1016/j.afos.2019.05.001
  • Zhang D, Wu Y, Li Z, et al. MiR-144-5p, an exosomal miRNA from bone marrow-derived macrophage in type 2 diabetes, impairs bone fracture healing via targeting Smad1. J Nanobiotechnology. 2021;19(1):226. doi:10.1186/s12951-021-00964-8
  • Zhang C, Bao LR, Yang YT, Wang Z, Li Y. M2巨噬细胞外泌体对高糖高胰岛素条件下小鼠骨髓间充质干细胞成骨分化的影响 [Role of M2 macrophage exosomes in osteogenic differentiation of mouse bone marrow mesenchymal stem cells under high-glucose and high-insulin]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2022;53(1):63–70. Chinese. doi:10.12182/20220160207
  • Yu L, Hu M, Cui X, et al. M1 macrophage-derived exosomes aggravate bone loss in postmenopausal osteoporosis via a microRNA-98/DUSP1/JNK axis. Cell Biol Int. 2021;45(12):2452–2463. doi:10.1002/cbin.11690
  • Cui H, He Y, Chen S, et al. Macrophage-Derived miRNA-containing exosomes induce peritendinous fibrosis after tendon injury through the miR-21-5p/Smad7 Pathway. Mol Ther Nucleic Acids. 2019;14:114–130. doi:10.1016/j.omtn.2018.11.006
  • Zhou M, Li B, Liu C, et al. M2 Macrophage-derived exosomal miR-501 contributes to pubococcygeal muscle regeneration. Int Immunopharmacol. 2021;101(PtB):108223. doi:10.1016/j.intimp.2021.108223
  • Yu Y, Sun B, Wang Z, et al. Exosomes from M2 macrophage promote peritendinous fibrosis posterior tendon injury via the MiR-15b-5p/FGF-1/7/9 pathway by delivery of circRNA-Ep400. Front Cell Dev Biol. 2021;9:595911. doi:10.3389/fcell.2021.595911
  • Ponzetti M, Rucci N. Updates on osteoimmunology: what’s new on the cross-talk between bone and immune system. Front Endocrinol. 2019;10:236. doi:10.3389/fendo.2019.00236
  • Terkawi MA, Matsumae G, Shimizu T, et al. Interplay between inflammation and pathological bone resorption: insights into recent mechanisms and pathways in related diseases for future perspectives. Int J Mol Sci. 2022;23:3. doi:10.3390/ijms23031786
  • Uenaka M, Yamashita E, Kikuta J, et al. Osteoblast-derived vesicles induce a switch from bone-formation to bone-resorption in vivo. Nat Commun. 2022;13(1):1066. doi:10.1038/s41467-022-28673-2
  • Garcia-Martin R, Wang G, Brandao BB, et al. MicroRNA sequence codes for small extracellular vesicle release and cellular retention. Nature. 2022;601(7893):446–451. doi:10.1038/s41586-021-04234-3
  • Hu Y, Wang Y, Chen T, et al. Exosome: function and application in inflammatory bone diseases. Oxid Med Cell Longev. 2021;2021:6324912. doi:10.1155/2021/6324912
  • Hassani K, Olivier M, Milon G. Immunomodulatory impact of leishmania-induced macrophage exosomes: a comparative proteomic and functional analysis. PLoS Negl Trop Dis. 2013;7(5):e2185. doi:10.1371/journal.pntd.0002185
  • Cypryk W, Lorey M, Puustinen A, Nyman TA, Matikainen S. Proteomic and bioinformatic characterization of extracellular vesicles released from human macrophages upon influenza A virus infection. J Proteome Res. 2017;16(1):217–227. doi:10.1021/acs.jproteome.6b00596
  • Cypryk W, Ohman T, Eskelinen EL, Matikainen S, Nyman TA. Quantitative proteomics of extracellular vesicles released from human monocyte-derived macrophages upon beta-glucan stimulation. J Proteome Res. 2014;13(5):2468–2477. doi:10.1021/pr4012552
  • Li F, Chung H, Reddy SV, et al. Annexin II stimulates RANKL expression through MAPK. J Bone Miner Res. 2005;20(7):1161–1167. doi:10.1359/JBMR.050207
  • Li YJ, Kukita A, Teramachi J, et al. A possible suppressive role of galectin-3 in upregulated osteoclastogenesis accompanying adjuvant-induced arthritis in rats. Lab Invest. 2009;89(1):26–37. doi:10.1038/labinvest.2008.111
  • Koh JM, Lee YS, Kim YS, et al. Heat shock protein 60 causes osteoclastic bone resorption via toll-like receptor-2 in estrogen deficiency. Bone. 2009;45(4):650–660. doi:10.1016/j.bone.2009.06.007
  • Pizzirani C, Ferrari D, Chiozzi P, et al. Stimulation of P2 receptors causes release of IL-1beta-loaded microvesicles from human dendritic cells. Blood. 2007;109(9):3856–3864. doi:10.1182/blood-2005-06-031377
  • Xin Y, Wang W, Mao E, Yang H, Targeting LS. NLRP3 Inflammasome alleviates synovitis by reducing pyroptosis in rats with experimental temporomandibular joint osteoarthritis. Mediators Inflamm. 2022;2022:2581151. doi:10.1155/2022/2581151
  • Goto Y, Ogawa Y, Tsumoto H, et al. Contribution of the exosome-associated form of secreted endoplasmic reticulum aminopeptidase 1 to exosome-mediated macrophage activation. Biochim Biophys Acta Mol Cell Res. 2018;1865(6):874–888. doi:10.1016/j.bbamcr.2018.03.009
  • Qi Y, Zhu T, Zhang T, et al. M1 macrophage-derived exosomes transfer miR-222 to induce bone marrow mesenchymal stem cell apoptosis. Lab Invest. 2021;101(10):1318–1326. doi:10.1038/s41374-021-00622-5
  • Kuehbacher A, Urbich C, Dimmeler S. Targeting microRNA expression to regulate angiogenesis. Trends Pharmacol Sci. 2008;29(1):12–15. doi:10.1016/j.tips.2007.10.014
  • Ortega FJ, Moreno M, Mercader JM, et al. Inflammation triggers specific microRNA profiles in human adipocytes and macrophages and in their supernatants. Clin Epigenetics. 2015;7:49. doi:10.1186/s13148-015-0083-3
  • Murray PJ, Allen JE, Biswas SK, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41(1):14–20. doi:10.1016/j.immuni.2014.06.008
  • Bondeson J, Blom AB, Wainwright S, et al. The role of synovial macrophages and macrophage-produced mediators in driving inflammatory and destructive responses in osteoarthritis. Arthritis Rheum. 2010;62(3):647–657. doi:10.1002/art.27290
  • Bai J, Zhang Y, Zheng X, et al. LncRNA MM2P-induced, exosome-mediated transfer of Sox9 from monocyte-derived cells modulates primary chondrocytes. Cell Death Dis. 2020;11(9):763. doi:10.1038/s41419-020-02945-5
  • Da-Wa ZX, Jun M, Chao-Zheng L, et al. Exosomes Derived from M2 macrophages exert a therapeutic effect via inhibition of the PI3K/AKT/mTOR pathway in rats with knee osteoarthritic. Biomed Res Int. 2021;2021:7218067. doi:10.1155/2021/7218067
  • Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376(9746):1094–1108. doi:10.1016/S0140-6736(10)60826-4
  • Radu AF, Bungau SG. Management of rheumatoid arthritis: an overview. Cells. 2021;10:11. doi:10.3390/cells10112857
  • Krzywinska E, Stockmann C. Hypoxia, metabolism and immune cell function. Biomedicines. 2018;6:2. doi:10.3390/biomedicines6020056
  • Zhu X, Shen H, Yin X, et al. Macrophages derived exosomes deliver miR-223 to epithelial ovarian cancer cells to elicit a chemoresistant phenotype. J Exp Clin Cancer Res. 2019;38(1):81. doi:10.1186/s13046-019-1095-1
  • Xie Y, Zhang L, Gao Y, Ge W, Tang P. The multiple roles of microrna-223 in regulating bone metabolism. Molecules. 2015;20(10):19433–19448. doi:10.3390/molecules201019433
  • Ismail N, Wang Y, Dakhlallah D, et al. Macrophage microvesicles induce macrophage differentiation and miR-223 transfer. Blood. 2013;121(6):984–995. doi:10.1182/blood-2011-08-374793
  • Wang B, Li Q, Dong J, Zhou D, Liu F. Comparisons of the surface micromotions of cementless femoral prosthesis in the horizontal and vertical levels: a network analysis of biomechanical studies. J Orthop Surg Res. 2020;15(1):293. doi:10.1186/s13018-020-01794-4
  • Yan SG, Chevalier Y, Liu F, et al. Metaphyseal anchoring short stem Hip arthroplasty provides a more physiological load transfer: a comparative finite element analysis study. J Orthop Surg Res. 2020;15(1):498. doi:10.1186/s13018-020-02027-4
  • Hodges NA, Sussman EM, Stegemann JP. Aseptic and septic prosthetic joint loosening: impact of biomaterial wear on immune cell function, inflammation, and infection. Biomaterials. 2021;278:121127. doi:10.1016/j.biomaterials.2021.121127
  • Baranowska A, Plusa T, Baranowski P, Szymczak Z, Dudek J. Czy aseptyczne obluzowanie protez stawów jest aseptyczne?[Is aseptic loosening of joint prostheses aseptic?]. Pol Merkur Lekarski. 2022;50(299):318–322. Polish.
  • Nich C, Takakubo Y, Pajarinen J, et al. Macrophages-Key cells in the response to wear debris from joint replacements. J Biomed Mater Res A. 2013;101(10):3033–3045. doi:10.1002/jbm.a.34599
  • Liu F, Dong J, Zhou D, Zhang Q. Identification of key candidate genes related to inflammatory osteolysis associated with vitamin E-Blended UHMWPE debris of orthopedic implants by integrated bioinformatics analysis and experimental confirmation. J Inflamm Res. 2021;14:3537–3554. doi:10.2147/JIR.S320839
  • Stanczyk J, Pedrioli DM, Brentano F, et al. Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum. 2008;58(4):1001–1009. doi:10.1002/art.23386
  • Yang JX, Xie P, Li YS, Wen T, Yang XC. Osteoclast-derived miR-23a-5p-containing exosomes inhibit osteogenic differentiation by regulating Runx2. Cell Signal. 2020;70:109504. doi:10.1016/j.cellsig.2019.109504
  • Chen YW, Hsieh O, Chen YA, Chiou LL, Chang PC. Randomized controlled clinical effectiveness of adjunct 660-nm light-emitting diode irradiation during non-surgical periodontal therapy. J Formos Med Assoc. 2020;119(1 Pt 1):157–163. doi:10.1016/j.jfma.2019.01.010
  • Song X, Xue Y, Fan S, Hao J, Deng R. Lipopolysaccharide-activated macrophages regulate the osteogenic differentiation of bone marrow mesenchymal stem cells through exosomes. PeerJ. 2022;10:e13442. doi:10.7717/peerj.13442
  • Rickel K, Fang F, Tao J. Molecular genetics of osteosarcoma. Bone. 2017;102:69–79. doi:10.1016/j.bone.2016.10.017
  • Liang X, Guo W, Ren T, et al. Macrophages reduce the sensitivity of osteosarcoma to neoadjuvant chemotherapy drugs by secreting Interleukin-1 beta. Cancer Lett. 2020;480:4–14. doi:10.1016/j.canlet.2020.03.019
  • Zhang H, Yu Y, Wang J, et al. Macrophages-derived exosomal lncRNA LIFR-AS1 promotes osteosarcoma cell progression via miR-29a/NFIA axis. Cancer Cell Int. 2021;21(1):192. doi:10.1186/s12935-021-01893-0
  • Yang M, Chen J, Su F, et al. Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Mol Cancer. 2011;10:117. doi:10.1186/1476-4598-10-117
  • Li C, Li R, Hu X, Zhou G, Jiang G. Tumor-promoting mechanisms of macrophage-derived extracellular vesicles-enclosed microRNA-660 in breast cancer progression. Breast Cancer Res Treat. 2022;192(2):353–368. doi:10.1007/s10549-021-06433-y
  • Takenaka M, Yabuta A, Takahashi Y, Takakura Y. Interleukin-4-carrying small extracellular vesicles with a high potential as anti-inflammatory therapeutics based on modulation of macrophage function. Biomaterials. 2021;278:121160. doi:10.1016/j.biomaterials.2021.121160
  • Udalova IA, Mantovani A, Feldmann M. Macrophage heterogeneity in the context of rheumatoid arthritis. Nat Rev Rheumatol. 2016;12(8):472–485. doi:10.1038/nrrheum.2016.91
  • Li H, Feng Y, Zheng X, et al. M2-type exosomes nanoparticles for rheumatoid arthritis therapy via macrophage re-polarization. J Control Release. 2022;341:16–30. doi:10.1016/j.jconrel.2021.11.019
  • Wu G, Zhang J, Zhao Q, et al. Molecularly engineered macrophage-derived exosomes with inflammation tropism and intrinsic heme biosynthesis for atherosclerosis treatment. Angew Chem Int Ed Engl. 2020;59(10):4068–4074. doi:10.1002/anie.201913700
  • Sun D, Zhuang X, Xiang X, et al. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol Ther. 2010;18(9):1606–1614. doi:10.1038/mt.2010.105
  • Yan F, Zhong Z, Wang Y, et al. Exosome-based biomimetic nanoparticles targeted to inflamed joints for enhanced treatment of rheumatoid arthritis. J Nanobiotechnology. 2020;18(1):115. doi:10.1186/s12951-020-00675-6
  • Zeng ZL, Xie H. Mesenchymal stem cell-derived extracellular vesicles: a possible therapeutic strategy for orthopaedic diseases: a narrative review. Biomater Transl. 2022;3(3):175–187. doi:10.12336/biomatertransl.2022.03.002
  • Xue X, Hu Y, Deng Y, Su J. Recent advances in design of functional biocompatible hydrogels for bone tissue engineering. Adv Funct Mater. 2021;31:19. doi:10.1002/adfm.202009432